title: Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes.
abstract: OBJECTIVE
  We have previously reported evidence of an inverse association between a urinary F(2)-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRAS cohort.
  
  
  METHODS
  This prospective study included 138 incident type 2 diabetes case and 714 noncase subjects. Four F(2)-isoprostanes (iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI) were assayed in baseline urine samples using liquid chromatography-tandem mass spectrometry.
  
  
  RESULTS
  Three F(2)-isoprostanes showed significant inverse associations with type 2 diabetes risk: the adjusted odds ratios were 0.52 (95% CI 0.39-0.67), 0.56 (0.42-0.73), 0.62 (0.48-0.79), and 0.91 (0.72-1.12) for iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI, respectively.
  
  
  CONCLUSIONS
  Our findings indicate that urinary F(2)-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying high-risk populations.
authors.affiliation: Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA. dora.ilyasova@duke.edu
authors.forename: Dora
authors.initials: D
authors.lastname: Il'yasova
authors.forename: Ivan
authors.initials: I
authors.lastname: Spasojevic
authors.forename: Karel
authors.initials: K
authors.lastname: Base
authors.forename: Haoyue
authors.initials: H
authors.lastname: Zhang
authors.forename: Frances
authors.initials: F
authors.lastname: Wang
authors.forename: Sarah P
authors.initials: SP
authors.lastname: Young
authors.forename: David S
authors.initials: DS
authors.lastname: Millington
authors.forename: Ralph B
authors.initials: RB
authors.lastname: D'Agostino
authors.forename: Lynne E
authors.initials: LE
authors.lastname: Wagenknecht
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000652:urine*; D016022:Case-Control Studies; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000517:prevention & control / Q000652:urine; D028441:F2-Isoprostanes / Q000652:urine*; D005260:Female; D018149:Glucose Intolerance / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D040242:Risk Reduction Behavior
chemical_list: D015415:Biomarkers; D028441:F2-Isoprostanes
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1506-10
references.pmid: 20501773
references.citation: Ann Epidemiol. 1995 Nov;5(6):464-72
references.pmid: 8680609
references.citation: Obes Res. 2005 Sep;13(9):1638-44
references.pmid: 16222068
references.citation: J Clin Endocrinol Metab. 1984 Nov;59(5):857-60
references.pmid: 6384259
references.citation: Antioxid Redox Signal. 2008 Aug;10(8):1405-34
references.pmid: 18522490
references.citation: Anal Biochem. 2010 Jul 15;402(2):191-3
references.pmid: 20361921
references.citation: Diabetologia. 2010 May;53(5):866-74
references.pmid: 20143044
references.citation: Diabetes Care. 2007 Oct;30(10):2529-35
references.pmid: 17586736
references.citation: Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):434-9
references.pmid: 12615693